Neurologic protection by amifostine.

Area of Science:

• Oncology
• Pharmacology
• Toxicology

Background:

• Amifostine is a cytoprotectant agent that can mitigate chemotherapy-induced toxicities.
• Preclinical studies show amifostine protects normal tissues from chemotherapy and radiation while maintaining anti-tumor effects.
• Clinical trials confirm amifostine's protective effects, notably against cisplatin-induced myelosuppression, nephrotoxicity, and neurotoxicity.

Purpose of the Study:

• To review the potential role of amifostine as a neuroprotectant against chemotherapy-induced neurotoxicity.
• To explore amifostine's ability to reduce dose-limiting neurotoxicity from agents like cisplatin, paclitaxel, and vinca alkaloids.
• To discuss how neuroprotection may improve patient treatment tolerance and allow for chemotherapy dose intensification.

Main Methods:

• Review of preclinical and clinical studies on amifostine's protective effects.
• Analysis of amifostine's efficacy in preventing neurotoxicity from various chemotherapeutic agents.
• Evaluation of amifostine's impact on normal tissue protection versus tumor cell cytotoxicity.

Main Results:

• Amifostine demonstrated protection in normal tissues including bone marrow, kidney, lung, and peripheral nerves in preclinical models.
• Clinical studies, including a randomized trial, confirmed amifostine's ability to protect against cisplatin-induced myelosuppression, nephrotoxicity, and neurotoxicity.
• Amifostine preserves the antineoplastic activity of chemotherapy and radiation in tumor tissues.

Conclusions:

• Amifostine shows significant potential as a neuroprotective agent in cancer therapy.
• Further clinical trials are warranted to investigate amifostine's use with multiple neurotoxic agents and in combination therapies.
• Comparing amifostine with other neuroprotective agents will be crucial for optimizing cancer treatment strategies.